Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | Updates from the MAHOGANY study in gastric cancer

Daniel Catenacci • 6 Jul 2020
ESMO WCGIC 2020
Gastric Cancer Gastroesophageal Cancer Gastrointestinal Cancer Antibodies Retifanlimab Tebotelimab

Daniel Catenacci, MD, University of Chicago, Chicago, IL, discusses results from the MAHOGANY study, (NCT02318329) evaluating the use of margetuximab combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) with or without chemotherapy in first-line therapy of advanced, metastatic HER2 positive gastroesophageal junction or gastric cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Daniel Catenacci

4:10
MAHOGANY: margetuximab and retifanlimab in HER2+, 1L unresectable/metastatic GEA
Daniel Catenacci • 27 Aug 2021
1:43
Gastroesophageal carcinoma with HER2 gene amplification
Daniel Catenacci • 27 Aug 2021
4:11
Personalized, neoantigen-directed immunotherapy in patients with advanced MSS-CRC, GEA and NSCLC
Daniel Catenacci • 27 Aug 2021
2:59
Clinical implications of HER2 in GI cancers
Daniel Catenacci • 19 May 2021

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals